View Item 

Show simple item record

Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?
dc.contributor.authorRabiee, Anahita
dc.contributor.authorGarcia-Tsao, Guadalupe
dc.contributor.authorTapper, Elliot B.
dc.date.accessioned2022-04-08T18:04:59Z
dc.date.available2023-04-08 14:04:58en
dc.date.available2022-04-08T18:04:59Z
dc.date.issued2022-03
dc.identifier.citationRabiee, Anahita; Garcia-Tsao, Guadalupe ; Tapper, Elliot B. (2022). "Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?." Clinical Liver Disease (3): 118-123.
dc.identifier.issn2046-2484
dc.identifier.issn2046-2484
dc.identifier.urihttps://hdl.handle.net/2027.42/172033
dc.publisherWiley Periodicals, Inc.
dc.titleNonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGastroenterology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172033/1/cld1182_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172033/2/cld1182.pdf
dc.identifier.doi10.1002/cld.1182
dc.identifier.sourceClinical Liver Disease
dc.identifier.citedreferenceBai W, Al‐Karaghouli M, Stach J, et al. Test–retest reliability and consistency of HVPG and impact on trial design: a study in 289 patients from 20 randomized controlled trials. Hepatology 2021. https://doi.org/10.1002/hep.32033.
dc.identifier.citedreferenceVillanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double‐blind, placebo‐controlled, multicentre trial. Lancet 2019; 393: 1597 ‐ 1608.
dc.identifier.citedreferenceHernández‐Gea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β‐blockers. Am J Gastroenterol 2012; 107: 418 ‐ 427.
dc.identifier.citedreferenceVillanueva C, Aracil C, Colomo A, et al. Acute hemodynamic response to β‐blockers and prediction of long‐term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 2009; 137: 119 ‐ 128.
dc.identifier.citedreferenceReiberger T, Ferlitsch A, Payer BA, et al. Non‐selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL‐6 in patients with cirrhosis. J Hepatol 2013; 58: 911 ‐ 921.
dc.identifier.citedreferenceGluud LL, Krag A. Banding ligation versus beta‐blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012; 8: CD004544.
dc.identifier.citedreferenceSersté T, Melot C, Francoz C, et al. Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017 ‐ 1022.
dc.identifier.citedreferenceChirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective β‐blockers and survival in patients with cirrhosis and ascites: a systematic review and meta‐analysis. Clin Gastroenterol Hepatol 2016; 14: 1096 ‐ 1104.e9.
dc.identifier.citedreferenceTéllez L, Ibáñez‐Samaniego L, Pérez del Villar C, et al. Non‐selective beta‐blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol 2020; 73: 1404 ‐ 1414.
dc.identifier.citedreferenceTergast TL, Kimmann M, Laser H, et al. Systemic arterial blood pressure determines the therapeutic window of non‐selective beta blockers in decompensated cirrhosis. Aliment Pharmacol Ther 2019; 50: 696 ‐ 706.
dc.identifier.citedreferenceAlbillos A, Bañares R, González M, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta‐analysis. Am J Gastroenterol 2007; 102: 1116 ‐ 1126.
dc.identifier.citedreferenceAbraldes J. Hemodynamic response to pharmacological treatment of portal hypertension and long‐term prognosis of cirrhosis. Hepatology 2003; 37: 902 ‐ 908.
dc.identifier.citedreferenceReiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non‐response to propranolol. Gut 2013; 62: 1634 ‐ 1641.
dc.identifier.citedreferenceGarcia‐Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823 ‐ 832.
dc.identifier.citedreferenceLebrec D, Corbic M, Nouel O, et al. Propranolol—a medical treatment for portal hypertension? Lancet 1980; 316: 180 ‐ 182.
dc.identifier.citedreferenceTurco L, Garcia‐Tsao G, Magnani I, et al. Cardiopulmonary hemodynamics and C‐reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol 2018; 68: 949 ‐ 958.
dc.identifier.citedreferenceVillanueva C, Albillos A, Genescà J, et al. Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension: Liver Failure/Cirrhosis/Portal Hypertension. Hepatology 2016; 63: 197 ‐ 206.
dc.identifier.citedreferenceGarcia‐Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65: 310 ‐ 335.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cld1182_am.pdf
Size:
755.6KB
Format:
PDF
View/Open
Name:
cld1182.pdf
Size:
1.051MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.